ASCO GU 2020: Immunotherapy combinations effective for brain metastases
Two small studies reported on patients whose kidney cancer had [...]
Nivolumab/ipilimumab combination extends treatment-free survival in kidney cancer patients
Immune checkpoint inhibitors (ICIs), such as nivolumab and ipilimumab have [...]
Alternative schedule ipilimumab plus nivolumab for first-line treatment of advanced kidney cancer
The combination of nivolumab with ipilimumab has been proven to [...]
Comparison of first-line immunotherapy combinations for advanced kidney cancer
In this paper, three clinical trials with immunotherapy combinations for [...]
ESMO 2019: Results from TITAN-RCC tailored immunotherapy clinical trial
Results from the TITAN-RCC clinical trial to assess tailored immunotherapy [...]
Nivolumab-ipilimumab combination shows promise for kidney cancer brain metastases
An interim analysis of study Checkmate 920 has shown that [...]
SMC approves nivolumab plus ipilimumab combination for advanced RCC
We are delighted to announce that the Scottish Medicines Consortium [...]
Predictive biomarkers in metastatic kidney cancer
A review published in European Urology Focus looks at tools [...]
First immunotherapy combination of ipilimumab plus nivolumab available to patients in England
We are very pleased to learn that the ipilimumab plus [...]
ASCO GU 2019: Nivolumab-ipilimumab survival benefit in advanced kidney cancer
New 30-month survival data from the CheckMate 214 study were [...]
